Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Hims & Hers Health (HIMS) Amortization of Deferred Charges (2020 - 2025)

Hims & Hers Health (HIMS) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $1.7 million as the latest value for Q4 2025.

Quarterly Amortization of Deferred Charges changed N/A to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $4.5 million for FY2025, N/A changed from the prior year.
Amortization of Deferred Charges hit $1.7 million in Q4 2025 for Hims & Hers Health, up from $144000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $1.7 million in Q4 2025 to a low of $144000.0 in Q1 2021.